Tech Company Financing Transactions
Vial Funding Round
Vial, based in San Francisco, secured $67 million from General Catalyst Partners, BoxGroup and Byers Capital.
Transaction Overview
Company Name
Announced On
11/30/2022
Transaction Type
Venture Equity
Amount
$67,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the clinical development of medicines.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1050 Battery St. 150
San Francisco, CA 94111
USA
San Francisco, CA 94111
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Vial is a next-generation tech-enabled CRO that delivers faster and 50%+ cheaper trials through end-to-end technology platform. Our team is a marriage of ClinOps leaders with over 150 years of experience at CROs and a best-in-class team of Engineers, Product Managers and Designs from Silicon Valley. Together, our team has built a technology platform to deliver on a generational opportunity to make trials radically more efficient.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Simon Burns
VP - Bus. Development
Dan Gallagher
VP - Finance
Will MacInnis
VP - Operations
Ananya Shah
VP - Sales
Andrew Brackin
Browse more venture capital transactions:
Prev: 11/29/2022: Igloo venture capital transaction
Next: 11/30/2022: Prismforce venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs